1. Redon J, Olsen MH, Cooper RS et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011; 32: 1424–31.
2. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension of the European Society of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31 (7): 1281–357.
4. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23.
5. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–9.
6. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013; c. 1.
7. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864–9.
8. Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5.
9. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–41.
10. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318–27.
11. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–5.
12. Mattace-Raso FU, van der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657–63.
13. Sehestedt T, Jeppesen J, Hansen TW et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883–91.
14. Sehestedt T, Jeppesen J, Hansen TW et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts.
 J Hypertens 2012; 30: 1928–36.
15. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121: 505–11.
16. Franklin S, Khan S, Wong ND et al. Is pulse pressure useful in predicting risk of coronary heart-disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
17. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–449.
18. Assmann G, Cullen P, Evers T et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26 (20): 2120–6.
19. Verdecchia P, Schillaci G, Borgioni C et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983–8.
20. Fernаndez-Escribano Hernаndez M, Suаrez Fernаndez C, Sаez Vaquero T et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp 2007; 207 (6): 284–90.
21. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375–80.
22. Fesler P, Safar ME, du Cailar G et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25 (9): 1915–20.
23. Arulkumaran N, Diwakar R, Tahir Z et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23 (2): 189–93.
24. Briet M et al. Longitudinal study: Central pulse pressure is an independent determinant of end stage renal desease. JASN 2011.
25. Perry M, Miller P, Fornoff J et al. Early predictor of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Pt. I): 587–94.
26. Abernethy J, Borhani NO, Hawkins CM et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2: 123–32.
27. Bihorac A, Tezcan H, Ozener C et al. Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens 2000; 13: 864–72.
28. Chen N, Zhou M, Yang M et al. Calcium channel blockers versus other classes of drugs for hypertension. Source: Cochrane Database Syst Rev 2010; 8: CD003654.
29. Nigel S, Beckett MB, Ch B et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358: 1887–98.
30. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens 2006; 19 (1): 113–21.
31. London G, Schmieder R, Calvo C. Applanation tonometry: arterial mechanical properties of indapamide SR vs candesartan and amlodipine: the X-CELLENT tonometry study. J Hypertens 2004; 22 (Suppl. 2): S116.
32. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Clin Drug Invest 2007; 27 (11): 734–52.
33. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118–23.
34. Bihorac A, Tezcan H, Ozener C et al. Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens 2000; 13: 864–72.
35. Et-Taouil K, Schiavi P, Levi BI, Plante GE. Sodium intake, large artery stiffness, and proteoglycans in the spontaneously hypertensive rat. Hypertension 2001; 38: 1172–6.
36. Benetos A et al. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Human Hypertens 1996; 10: 77–82.
37. Emeriau JP, Knauf H, Pujadas JO et al. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19 (2): 343–50.
38. Сайгитов Р.Т., Глезер М.Г. Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований). Артериальная гипертензия. 2010; 1: 52–61.
39. London GM, Asmar RG, O’Rourke MF, Safar ME. REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9.
40. Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В. и др. Результаты Российской научно-практической программы АРГУС-2: возможности улучшения контроля артериальной гипертонии путем рационального использования диуретиков. Лечебное дело. 2007; 3.
41. Чукаева И.И., Спирякина Я.Г. Индапамид-ретард – препарат выбора у пожилых пациентов с артериальной гипертонией. Рос. кардиол. журн. 2013; 5 (103): 56–60.
42. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683–9.

И.И.Чукаева, М.В.Соловьева, Я.Г.Спирякина

Кафедра поликлинической терапии №2 лечебного факультета ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва